The first end level was the security and tolerability of sifalimumab. Treatment-emergent adverse events (AEs) and serious AEs (SAEs) and their severity, final result, and any connection to your examine medication ended up recorded via the investigator through the examine. AEs ended up thought of very likely to be related https://franciscomtyeg.gynoblog.com/30232346/detailed-notes-on-m3541